Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

William C. Knowler, Richard F. Hamman, Sharon L. Edelstein, Elizabeth Barrett-Connor, David A. Ehrmann, Elizabeth A. Walker, Sarah E. Fowler, David M. Nathan, Steven E. Kahn

Research output: Contribution to journalArticle

360 Citations (Scopus)

Abstract

The Diabetes Prevention Program (DPP) was a randomized clinical trial of prevention of type 2 diabetes in high-risk people. Troglitazone, an insulin-sensitizing agent, was used initially but was discontinued during the trial. Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer-term results after troglitazone were discontinued. From 1996 to 1998, participants were randomly assigned to treatment with metformin (n = 587), troglitazone (n = 585), double placebo (n = 582), or intensive lifestyle intervention (ILS) (n = 589). Because of concern regarding its liver toxicity, the troglitazone arm was discontinued in June 1998, after which follow-up of all participants continued. During the mean 0.9 year (range 0.5-1.5 years) of troglitazone treatment, the diabetes incidence rate was 3.0 cases/100 person-years, compared with 12.0, 6.7, and 5.1 cases/100 person-years in the placebo, metformin, and ILS participants (P < 0.001, troglitazone vs. placebo; P = 0.02, troglitazone vs. metformin; P = 0.18, troglitazone vs. ILS). This effect of troglitazone was in part due to improved insulin sensitivity with maintenance of insulin secretion. During the 3 years after troglitazone withdrawal, the diabetes incidence rate was almost identical to that of the placebo group. Troglitazone, therefore, markedly reduced the incidence of diabetes during its limited period of use, but this action did not persist. Whether other thiazolidinedione drugs used for longer periods can safely prevent diabetes remains to be determined.

Original languageEnglish (US)
Pages (from-to)1150-1156
Number of pages7
JournalDiabetes
Volume54
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

troglitazone
Type 2 Diabetes Mellitus
Metformin
Placebos
Life Style
Incidence
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Knowler, W. C., Hamman, R. F., Edelstein, S. L., Barrett-Connor, E., Ehrmann, D. A., Walker, E. A., ... Kahn, S. E. (2005). Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes, 54(4), 1150-1156. https://doi.org/10.2337/diabetes.54.4.1150

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. / Knowler, William C.; Hamman, Richard F.; Edelstein, Sharon L.; Barrett-Connor, Elizabeth; Ehrmann, David A.; Walker, Elizabeth A.; Fowler, Sarah E.; Nathan, David M.; Kahn, Steven E.

In: Diabetes, Vol. 54, No. 4, 04.2005, p. 1150-1156.

Research output: Contribution to journalArticle

Knowler, WC, Hamman, RF, Edelstein, SL, Barrett-Connor, E, Ehrmann, DA, Walker, EA, Fowler, SE, Nathan, DM & Kahn, SE 2005, 'Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program', Diabetes, vol. 54, no. 4, pp. 1150-1156. https://doi.org/10.2337/diabetes.54.4.1150
Knowler WC, Hamman RF, Edelstein SL, Barrett-Connor E, Ehrmann DA, Walker EA et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005 Apr;54(4):1150-1156. https://doi.org/10.2337/diabetes.54.4.1150
Knowler, William C. ; Hamman, Richard F. ; Edelstein, Sharon L. ; Barrett-Connor, Elizabeth ; Ehrmann, David A. ; Walker, Elizabeth A. ; Fowler, Sarah E. ; Nathan, David M. ; Kahn, Steven E. / Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. In: Diabetes. 2005 ; Vol. 54, No. 4. pp. 1150-1156.
@article{912f0f97507247d2bb20723e385b0494,
title = "Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program",
abstract = "The Diabetes Prevention Program (DPP) was a randomized clinical trial of prevention of type 2 diabetes in high-risk people. Troglitazone, an insulin-sensitizing agent, was used initially but was discontinued during the trial. Troglitazone therapy was compared with other DPP interventions, considering both the short-term {"}in-trial{"} results and the longer-term results after troglitazone were discontinued. From 1996 to 1998, participants were randomly assigned to treatment with metformin (n = 587), troglitazone (n = 585), double placebo (n = 582), or intensive lifestyle intervention (ILS) (n = 589). Because of concern regarding its liver toxicity, the troglitazone arm was discontinued in June 1998, after which follow-up of all participants continued. During the mean 0.9 year (range 0.5-1.5 years) of troglitazone treatment, the diabetes incidence rate was 3.0 cases/100 person-years, compared with 12.0, 6.7, and 5.1 cases/100 person-years in the placebo, metformin, and ILS participants (P < 0.001, troglitazone vs. placebo; P = 0.02, troglitazone vs. metformin; P = 0.18, troglitazone vs. ILS). This effect of troglitazone was in part due to improved insulin sensitivity with maintenance of insulin secretion. During the 3 years after troglitazone withdrawal, the diabetes incidence rate was almost identical to that of the placebo group. Troglitazone, therefore, markedly reduced the incidence of diabetes during its limited period of use, but this action did not persist. Whether other thiazolidinedione drugs used for longer periods can safely prevent diabetes remains to be determined.",
author = "Knowler, {William C.} and Hamman, {Richard F.} and Edelstein, {Sharon L.} and Elizabeth Barrett-Connor and Ehrmann, {David A.} and Walker, {Elizabeth A.} and Fowler, {Sarah E.} and Nathan, {David M.} and Kahn, {Steven E.}",
year = "2005",
month = "4",
doi = "10.2337/diabetes.54.4.1150",
language = "English (US)",
volume = "54",
pages = "1150--1156",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

AU - Knowler, William C.

AU - Hamman, Richard F.

AU - Edelstein, Sharon L.

AU - Barrett-Connor, Elizabeth

AU - Ehrmann, David A.

AU - Walker, Elizabeth A.

AU - Fowler, Sarah E.

AU - Nathan, David M.

AU - Kahn, Steven E.

PY - 2005/4

Y1 - 2005/4

N2 - The Diabetes Prevention Program (DPP) was a randomized clinical trial of prevention of type 2 diabetes in high-risk people. Troglitazone, an insulin-sensitizing agent, was used initially but was discontinued during the trial. Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer-term results after troglitazone were discontinued. From 1996 to 1998, participants were randomly assigned to treatment with metformin (n = 587), troglitazone (n = 585), double placebo (n = 582), or intensive lifestyle intervention (ILS) (n = 589). Because of concern regarding its liver toxicity, the troglitazone arm was discontinued in June 1998, after which follow-up of all participants continued. During the mean 0.9 year (range 0.5-1.5 years) of troglitazone treatment, the diabetes incidence rate was 3.0 cases/100 person-years, compared with 12.0, 6.7, and 5.1 cases/100 person-years in the placebo, metformin, and ILS participants (P < 0.001, troglitazone vs. placebo; P = 0.02, troglitazone vs. metformin; P = 0.18, troglitazone vs. ILS). This effect of troglitazone was in part due to improved insulin sensitivity with maintenance of insulin secretion. During the 3 years after troglitazone withdrawal, the diabetes incidence rate was almost identical to that of the placebo group. Troglitazone, therefore, markedly reduced the incidence of diabetes during its limited period of use, but this action did not persist. Whether other thiazolidinedione drugs used for longer periods can safely prevent diabetes remains to be determined.

AB - The Diabetes Prevention Program (DPP) was a randomized clinical trial of prevention of type 2 diabetes in high-risk people. Troglitazone, an insulin-sensitizing agent, was used initially but was discontinued during the trial. Troglitazone therapy was compared with other DPP interventions, considering both the short-term "in-trial" results and the longer-term results after troglitazone were discontinued. From 1996 to 1998, participants were randomly assigned to treatment with metformin (n = 587), troglitazone (n = 585), double placebo (n = 582), or intensive lifestyle intervention (ILS) (n = 589). Because of concern regarding its liver toxicity, the troglitazone arm was discontinued in June 1998, after which follow-up of all participants continued. During the mean 0.9 year (range 0.5-1.5 years) of troglitazone treatment, the diabetes incidence rate was 3.0 cases/100 person-years, compared with 12.0, 6.7, and 5.1 cases/100 person-years in the placebo, metformin, and ILS participants (P < 0.001, troglitazone vs. placebo; P = 0.02, troglitazone vs. metformin; P = 0.18, troglitazone vs. ILS). This effect of troglitazone was in part due to improved insulin sensitivity with maintenance of insulin secretion. During the 3 years after troglitazone withdrawal, the diabetes incidence rate was almost identical to that of the placebo group. Troglitazone, therefore, markedly reduced the incidence of diabetes during its limited period of use, but this action did not persist. Whether other thiazolidinedione drugs used for longer periods can safely prevent diabetes remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=15944395414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944395414&partnerID=8YFLogxK

U2 - 10.2337/diabetes.54.4.1150

DO - 10.2337/diabetes.54.4.1150

M3 - Article

C2 - 15793255

AN - SCOPUS:15944395414

VL - 54

SP - 1150

EP - 1156

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 4

ER -